Abstract: Precursors useful for vapor phase deposition processes, e.g., CVD/ALD, to form metal-containing films on substrates. The precursors include, in one class, a central metal atom M to which is coordinated at least one ligand of formula (I): wherein: R1, R2 and R3 are each independently H or ogano moieties; and G1 is an electron donor arm substituent that increases the coordination of the ligand to the central metal atom M; wherein when G1 is aminoalkyl, the substituents on the amino nitrogen are not alkyl, fluoroalkyl, cycloaliphatic, or aryl, and are not connected to form a ring structure containing carbon, oxygen or nitrogen atoms. Also disclosed are ketoester, malonate and other precursors adapted for forming metal-containing films on substrates, suitable for use in the manufacture of microelectronic device products such as semiconductor devices and flat panel displays.

Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for initiating the polymerization of aminoacid-N-carboxyanhydride (NCA) monomer by combining the monomer with an amido-containing metallacycle, for making self assembling amphiphilic block copolypeptides and related protocols for adding oligo(ethyleneglycol) functionalized aminoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains. Additional methods include means of adding an end group to the carboxy terminus of a polyaminoacid chain by reacting an alloc-protected amino acid amide with a transition metal-donor ligand complex to forming an amido-amidate metallacycle for use in further polymerization reactions. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.

Abstract: A process for synthesizing an organic transition metal complex compound with an atom group having an electron-donor ability, in an industrially and economically advantageous manner, without a compound having a proton-donor ability being a metal salt, and a metathesis catalyst produced with the use of the above process, are provided. A process for producing an organic transition metal complex compound in which an atom group having an electron-withdrawing ability can be converted into an atom group having a stronger electron-donor ability, by contacting an compound having a proton-donor ability with the organic transition metal complex compound with an atom group having an electron-withdrawing ability, in the presence of an basic compound, and a metathesis catalyst of which the content of an alkali metal is reduced, and which is obtainable with the use of the above process, are provided.

Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

Abstract: A theme of the present invention is to provide a new transition metal complex, useful as a photosensitizer dye for a photoelectric conversion element having an excellent durability and a high photoelectric conversion characteristic. The present invention provides a bivalent transition metal complex constituted of (i) a bipyridyl polyacidic ligand, such as a dicarboxybipyridyl (dcbpy) ligand, as an adsorption site for adsorption onto titanium dioxide particle surfaces; (ii) a ligand, selected from the group consisting of an isothiocyanato group, an isocyanato group, and an isoselenocyanato group and enabling absorption and excitation at long wavelengths and charge transfer; and (iii) a bipyridyl (bpy) ligand, having an alkyl group or an alkoxy group, preferably a long-chain alkyl group, and a conjugately bonded thienylvinylene group, aminophenylenevinylene group, etc.

Abstract: The present invention relates to metal complexes of the general formulae I to V, in particular as emitter molecules in organic electronic devices, to ligands of the general formulae Ia to Va, and to the use thereof for the preparation of metal complexes, to a layer and an electronic device which comprise the compounds according to the invention, and to a process for the preparation of the compounds according to the invention.

Abstract: The invention relates to a chiral iridium aqua complex of formula (1): wherein R1 and R2 are the same or different and each is an aryl group optionally having at least one substituent selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkoxy group having 1 to 6 carbon atoms, a nitro group, a carboxyl group and a cyano group, or the like; and wherein R3 and R4 are the same or different and each is an alkyl group or the like, as well as the use of such a chiral iridium aqua complex for asymmetric transfer hydrogenation.

Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.

Abstract: The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.

Abstract: The invention provides a method for producing an iridium complex with a high yield at a low temperature, and an organic electroluminescence device (organic EL device) having an light output high in efficiency and high luminance in a range from blue to red region. An iridium complex for the organic EL device is produced from an iridium complex having a 4-membered ring structure as an auxiliary ligand.

Abstract: Transition metal complexes of selected monoanionic phosphine ligands, which also contain a selected Group 15 or 16 (IUPAC) element and which are coordinated to a Group 3 to 11 (IUPAC) transition metal or a lanthanide metal, are polymerization catalysts for the (co)polymerization of olefins such as ethylene and ?-olefins, and the copolymerization of such olefins with polar group-containing olefins. These and other nickel complexes of neutral and monoanionic bidentate ligands copolymerize ethylene and polar comonomers, especially acrylates, at relatively high ethylene pressures and surprisingly high temperatures, and give good incorporation of the polar comonomers and good polymer productivity. These copolymers are often unique structures, which are described.

Abstract: The present invention provides a reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3?-diaminobenzidine and its analogues. The present invention also provides to a process for the preparation of a reusable transition metal complex catalyst. The present invention further provides a process for the preparation of 3,3?-diaminobenzidine (DAB) or 3,3?,4,4? Tetraminobiphenyl (TAB) using reusable transition metal complex catalyst. The high quality 3,3?-diaminobenzedine (DAB) and its analogues are prepared by coupling 4-halo-2-nitroaniline to 3,3?-dinitrobenzidine (DNB) using transition metals as catalysts followed by reduction of 3,3?-dinitrobenzidine to the corresponding substituted 3,3?-diaminobenzidine of formula 1 in high yields.

Abstract: The present invention relates to metallocene-based phosphine ligands having chirality at phosphorus and at least one other element of chirality (planar chirality and/or chirality at carbon); and to the use of such ligands in asymmetric transformation reactions to generate high enantiomeric excesses of formed compounds. A method for the preparation of ligands according to the invention involving the conversion of the ortho-lithiated substituted metallocene to a phosphine chiral at phosphorus is also disclosed.

Abstract: Metal complexes of formula I and IA and polymers derived from the complexes are useful in optoelectronic devices wherein M is Ir, Co or Rh; is a cyclometallated ligand; R1 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl; R2 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl; and at least one of R1 and R2 is other than hydrogen; R1a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl; R2a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl; and at least one of R1a and R2a is substituted alkyl, substituted aryl, substituted arylalkyl, and at least one substitutent of the substituted alkyl, substituted aryl, or substituted arylalkyl is a polymerizable group.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The subject invention concerns biotin-conjugated platinum complexes that exhibit direct and indirect (immunological) antitumor cell activity. The subject invention also concerns the biotin-platinum complexes of the invention that have another molecule, such as an antibody, a ligand, a receptor, etc., bound to the biotin moiety. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: This invention relates to processes for the production of organometallic compounds represented by the formula M(L)3 wherein M is a Group VIII metal, e.g., ruthenium, and L is the same or different and represents a substituted or unsubstituted amidinato group or a substituted or unsubstituted amidinato-like group, which process comprises (i) reacting a substituted or unsubstituted metal source compound, e.g., ruthenium (II) compound, with a substituted or unsubstituted amidinate or amidinate-like compound in the presence of a solvent and under reaction conditions sufficient to produce a reaction mixture comprising said organometallic compound, e.g., ruthenium (III) compound, and (ii) separating said organometallic compound from said reaction mixture. The organometallic compounds are useful in semiconductor applications as chemical vapor or atomic layer deposition precursors for film depositions.

Abstract: Novel phosphine-free non-ionic single catalysts, and method for making such catalysts, for the homo-polymerization and copolymerization of olefins such as ethylene, ?-olefins and functionalized olefins without the use of additional co-activators, are disclosed. These phosphine-free non-ionic single catalysts are also active for co-polymerization of olefins with monomers with polar functionalities. The catalyst of this invention comprise of a late transition metal with a chelating monoanionic ligand, an R group and a neutral 2 electron donor ligand. Catalysts are prepared by the oxidative addition of benzylhalide (halide=Cl, Br or I) to an appropriate metal source in the presence of a stabilizing agent, such as nitrogen based ligands, followed by the addition of the deprotonated form of the chelating ligand.

Abstract: A new platinum complex which has strong antitumor activity and has effect with smaller doses and a pharmaceutical composition containing the same are provided. A spiro[4,4]nonane-1,6-diamineplatinum(II) complex which is represented by a following general formula (A). (In the formula, X and Y are same or different, and X and Y represent halogen atoms respectively, or X and Y cooperatively represent a divalent residue which is described by a formula (Z).) The platinum complex has a strong antitumor activity and is efficacious as a therapeutic agent for malignant tumors.

Abstract: The invention provides a chiral iridium aqua complex which has good preservation stability, can be easily produced, and enables asymmetric transfer hydrogenation in a higher yield and with higher stereoselectivity.

Abstract: This invention relates a method for the preparation of platinum(II) oxalato complexes from their dihalogenoplatinum(II) precursors having either neutral monodentate or bidentate non-leaving co-ligands. Of particular interest is oxaliplatin. The method includes the step of reacting a halogenoplatinum(II) complex containing a neutral monodentate or bidentate ligand with an oxalate in a non-aqueous solvent or a mixed solvent system. The mixed solvent system is solvent mixture containing a non-aqueous solvent and water. According to the present invention, the non-aqueous solvent is an alcohol.

Abstract: The present invention is an optically active organic acidate-bridged dinuclear platinum(II) complex represented by the general formula (I): or the general formula (I?): (wherein R1 and R2 are the same or different and each represent a hydrogen atom or an alkyl group, or form an alkylene group by binding to each other at the ends thereof; R3 and R4 are the same or different and each represent a hydrogen atom or an alkyl group, or form an alkylene group by binding to each other at the ends thereof; A represents a single bond or a methylene group; and X? represents an anion). The complex of the present invention has an excellent anticancer activity, and is useful as medicine, especially an anticancer agent.

Abstract: The present invention relates to transition-metal complexes of the general formula I or II, in particular as emitter molecules in organic electronic devices, to a layer and to an electronic device which comprise the compounds according to the invention, and to a process for the preparation of the compounds according to the invention.

Abstract: This invention provides a method for producing an optically active aziridine compound or amine compound, which uses as a catalyst a Ru(salen)(CO) complex represented by the following formula (I) or its enantiomer having a high stability, in a high turnover number (TON) and a high enantioselectivity. In the formula (I), Ar is represented by the following formula (VI) or (VII), wherein in the formula (VI), Xs are independently a halogen or a halogenated alkyl group and R1 and R2s are independently hydrogen or an alkyl group or a trialkylsilyl group having a carbon number of 1-4, and in the formula (VII), R3 is a bulky group.

Abstract: The present invention describes a process for the preparation of homoleptic and heteroleptic tris-ortho-metallated metal compounds which are used as coloring components as functional materials in a number of different applications which can be ascribed to the electronics industry in the broadest sense.

Abstract: The present invention relates to a process for preparing palladium complexes. In particular, the present invention relates to a process in which ammoniacal complexes of palladium (hydrogen)carbonate are converted into complexes with oligoamine ligands.

Abstract: To provide a catalyst that has sufficient catalytic activity as a platinum catalyst and yet is readily separated from a target material and can be reused. A resin-supported platinum cluster catalyst containing a resin layer comprising a platinum particle core, the average diameter of which is from 1 nm to 10 nm, and a compound containing nitrogen (general formula R1NH2) surrounding the core.

Abstract: The invention relates to a method for the preparation of platinum (II) complexes, in particular dicarboxylatoplatinum (II) complexes containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a bis-dicarboxylatoplatinate (II) species with a suitable neutral bidentate ligand to form a neutral dicarboxylatoplatinum (II) complex and, if necessary, recrystallizing the product to form a pure dicarboxylatoplatinum (II) complex containing a neutral bidentate ligand. The invention also relates to a method for producing a bis-dicarboxylatoplatinate (II) species, and to new platinum (II) complexes that can be made by the method of the invention.

Abstract: This invention relates to a method for the preparation of a platinum(II) complex containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a halogenoplatinum complex containing a neutral bidentate ligand with an oxalate salt in a solvent, wherein more than 1 g/L of the oxalate salt is soluble in the solvent. The invention also relates to new platinum(II) complexes.

Abstract: The invention relates to an enantiomerically enriched chiral compound comprising a transition metal M, which comprises four, five or six coordinating groups of which at least one pair is linked together to form a bidentate ligand, in which M is directly bound via one single ?-bond to a carbon atom of an optionally substituted and/or optionally fused (hetero)aromatic ring of said bidentate ligand and in which M is directly bound to a nitrogen atom of a primary or secondary amino group of said bidentate ligand, thereby forming a metallacycle between said bidentate ligand and the metal M, said metal M being selected from the metals of groups 8 and 9 of the Periodic Table of the Elements, in particular iron, ruthenium, osmium, cobalt, rhodium, or iridium. The chiral compound can be used as a catalyst, preferably in an asymmetric transfer hydrogenation process.

Abstract: Provided are nitroplatinum(IV) complexes containing a bidentate dicarboxylate ligand (e.g., oxalate) which maybe useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: This invention relates to processes for the production of organometallic compounds represented by the formula M(L)3 wherein M is a Group VIII metal, e.g., ruthenium, and L is the same or different and represents a substituted or unsubstituted amidinato group or a substituted or unsubstituted amidinato-like group, which process comprises (i) reacting a substituted or unsubstituted metal source compound, e.g., ruthenium (II) compound, with a substituted or unsubstituted amidinate or amidinate-like compound in the presence of a solvent and under reaction conditions sufficient to produce a reaction mixture comprising said organometallic compound, e.g., ruthenium (III) compound, and (ii) separating said organometallic compound from said reaction mixture. The organometallic compounds are useful in semiconductor applications as chemical vapor or atomic layer deposition precursors for film depositions.

Abstract: Methods to determine drug hydrophobicity and to quantify changes in drug hydrophobicity that optimize drug function by means of differential scanning calorimetry of an endothermic phase transition of a base protein-based polymer, specifically of an elastic-contractile model protein, to which is attached the drug to be evaluated for its hydrophobicity in terms of the change in Gibbs free energy for hydrophobic association, ?GHA have been developed. Also described herein is the preparation of nanoparticles comprised of protein-based polymers, specifically of elastic-contractile model proteins, designed for the binding and desired release rate of a specific drug or class of drugs. Further described herein is a means of targeting the drug-laden nanoparticle to a cell by means of decorating the nanoparticle surface with a molecular entity that selectively binds to the diseased cell or disease causing organism, e.g.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.

Abstract: Briefly described, embodiments of this disclosure include transition-metal charge-transport materials, methods of forming transition-metal charge-transport materials, and methods of using the transition-metal charge-transport materials.

Abstract: A compound of general formula (I): in which: R is selected from the group consisting of (C1-C25)alkyl, (C2-C25)alkenyl, aryl, (C7-C10)aralkyl; n and m are each independently an integer of two to eight; p is one or two; A is selected from the group consisting of —B—, —B—(CH2)r—B—, —B—(CH2)r—B—(CH2)z—B—, wherein r and z are an integer from 2 to 8, B is a —NR1— or —N(R2)2+ 1/pQ?p group, in which R1 is selected from hydrogen, (C1-C4)alkyl, (C1-C4)acyl, tert-butoxycarbonyl, and R2 is selected from hydrogen and (C1-C4)alkyl; Q?p is an anion selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R3COO? wherein R3 has the same meanings as R, independently from one another and R4—O—SO3? wherein R4 is (C2-C14)alkyl with the proviso that, when Q?p is selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R is not (C1-C4)alkyl.

Abstract: The invention relates to novel metal complexes. Said compounds can be used as functional material in a series of different applications which in the broadest sense can be attributed to the electronics industry. The inventive compounds are described by the formula (1) and by compounds (1) to (52).

Abstract: The present invention relates to a process for preparing cycloplatinated platinum(II) complexes, platinum(II) complexes prepared by this process and the use thereof for the treatment of tumor diseases and/or hemo blastoses.

Abstract: This invention relates to processes for the production of organometallic compounds represented by the formula M(L)3 wherein M is a Group VIII metal, e.g., ruthenium, and L is the same or different and represents a substituted or unsubstituted amidinato group or a substituted or unsubstituted amidinato-like group, which process comprises (i) reacting a substituted or unsubstituted metal source compound, e.g., ruthenium (II) compound, with a substituted or unsubstituted amidinate or amidinate-like compound in the presence of a solvent and under reaction conditions sufficient to produce a reaction mixture comprising said organometallic compound, e.g., ruthenium (III) compound, and (ii) separating said organometallic compound from said reaction mixture. The organometallic compounds are useful in semiconductor applications as chemical vapor or atomic layer deposition precursors for film depositions.

Abstract: The invention relates to novel metal complexes. Said compounds can be used as functional materials in a series of different types of applications that can be attributed in the broadest sense to the electronics industry The inventive compounds are defined by formula (1).

Abstract: The present invention provides an organic metal compound, a ligand, an asymmetric catalyst, and a process for preparing optically-active alcohols using the asymmetric catalyst.

Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.

Abstract: Disclosed is a stable aqueous formulation of a platin derivative, particularly oxaliplatin. The selected stabilizing additive is effective even in very small concentrations.

Abstract: Disclosed are novel metathesis catalysts of the formula wherein R1, R2, R3, R4, R5, R6, X1, X2, L and Y are as described herein, a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.

Abstract: This inventive subject matter relates to novel transitional metal complexes of Quinoxalines, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity. The present invention relates to new substituted Quinoxaline compounds, their tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to the pharmaceutically acceptable salts of the compounds, tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to compositions of any of the aforementioned embodiments together with pharmaceutically acceptable carriers, and to uses of any of the aforementioned embodiments, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer.

Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.